

## BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13

NEW YORK and PETACH TIKVAH, Israel, Aug. 6, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report second quarter 2015 financial results on Thursday, August 13, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:00am Eastern Time to discuss the financial results and answer questions.

### **Conference Call & Webcast**

**Thursday, August 13, 2015 at 8:00 a.m. EST/5:00 a.m. PST**

Domestic: 888-329-8893  
Israel: 1 80 924 5906  
International: 719-325-2354  
Conference ID: 5122591  
Webcast: <http://public.viavid.com/player/index.php?id=115681>

**Replay will be available through August 27, 2015**

Domestic: 877-870-5176  
International: 858-384-5517  
Conference ID: 5122591

### **About BrainStorm Cell Therapeutics Inc.**

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at [www.brainstorm-cell.com](http://www.brainstorm-cell.com).

Logo - <http://photos.prnewswire.com/prnh/20141006/150511>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-report-second-quarter-2015-financial-results-on-thursday-august-13-300124872.html>

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media - Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460, [info@brainstorm-cell.com](mailto:info@brainstorm-cell.com); or Investors - Michael Wood, LifeSci Advisors, LLC, 646-597-6983, [mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)

---

Additional assets available online:  [Photos \(1\)](#)

<https://ir.brainstorm-cell.com/2015-08-06-BrainStorm-Cell-Therapeutics-to-Report-Second-Quarter-2015-Financial-Results-on-Thursday-August-13>